Jerusalem Mayor Nir Barkat Visits BioTechnology Park at Hadassah Ein Kerem

Mayor Calls the Jerusalem BioPark a Central Element in the Making of Jerusalem
into a Biotechnological Center Which Will Create Many Jobs in the City

JERUSALEM--(Business Wire)--
Hadasit, the technology transfer company of Hadassah University Medical Center,
announced that Jerusalem Mayor Nir Barkat visited the new Hadassah Medical
Center Hebrew University Biotechnology Park (JBP-Jerusalem BioPark) Ein-Kerem at
Hadassah University Hospital`s Ein Kerem campus today.

The visit coincided with the mayor`s June 15th announcement to invest NIS 100
million in the development of the capital's biomedical industry over the next
five years to create jobs and attract local and foreign businesses to establish
a presence in the city. The JBP is a cornerstone of this plan and is heralded as
first of its kind in Israel.

Mayor Barkat said, "The municipality and the Jerusalem Development Authority are
available to the JBP and support plans to extend the Jerusalem light rail train
to the BioPark and Hadassah Ein Kerem campus."

He continued, "Hadassah University Medical Center is a world class medical
facility; Hadasit is a novelty amongst technology transfer companies, and
Hadasit Bio Holdings (HBL), its publicly traded subsidiary, adds additional
elements of attraction for the investment community such as liquidity,
transparency and diversity. Hebrew University is a prime academic institution.
Indeed there is much potential here."

Mayor Barkat concluded, "Hadassah, Hadasit, HBL and HU have successfully pushed
boundaries and pioneered new terrain in terms of the marriage of science and
business. Today, we bear witness to a vision realized, the beginnings of a
thriving biopark, the essential infrastructure element to compliment the
existing innovation and commercialization programs already in place. It is a
great pride that all of the scientific creativity and commercial progress at the
Hadassah Ein Kerem campus is attracting global interest."

The mayor`s visit at JBP was hosted by Professor Shlomo Mor-Yosef, Director
General of Hadassah Medical Organization and chairman of the board of Hadasit.
The visit was attended by Elchanan HaCohen, vice president & director general of
the Hebrew University of Jerusalem, Avraham Kuznitsky, founder and owner of
Minrav, the heads of the departments at Hadassah University Hospital Ein Kerem,
the CEO and chairman of HBL, chief scientific officers of HBL`s nine portfolio
companies, including Cell Cure, Thrombotech, ConjuGate, TKsignal, InCure,
ProtAb, Tolarex, Verto, and KAHR Medical, as well as the staff of the HCRC.

Professor Mor-Yosef said, "Mayor Barkat, we hope that you will join the efforts
of bringing additional businesses to the JBP by introducing incentives."

"It is an honor to host you today Mr. Mayor. Your firm commitment to supporting
and growing the life science industry in Jerusalem is an inspiration to all of
us, and especially, the hard working scientists and company CEOs who have
already chosen to innovate at the Jerusalem BioPark," said Dr. Rafi Hofstein,
chairman of the board of HBL.

Mr. HaCohen said, "The massive infrastructure within the campus and the
combination of the Hebrew University and Hadassah Medical Center are ideal for
leveraging the economic and scientific capabilities of Jerusalem, especially in
high tech where Jerusalem enjoys a relative advantage."

The JBP, a joint project of Hadassah and the Hebrew University, was constructed
by Minrav, one of Israel's leading real estate developers. The facility, which
just recently opened it doors, comprises customized offices and access to
Hadassah's state of the art Clinical Research Center (HCRC) which provides
pharmaceutical, biotechnology and medical device companies a complete package of
services and facilities for drug and device clinical studies. HCRC services
include the availability of Hadassah`s dedicated, top rate, GCP qualified
clinical team, a large patient pool, a certified GMP facility and a research
center with standard operating procedures (SOP's) to ensure quality control. JBP
is also intended to be a center where occupants may benefit from the massive
pool of expertise and innovation within Hadassah Medical Center, the hospital
with the highest rate of translational R&D in Israel, as well as the free flow
of ideas and symbiotic collaborations.

About Hadasit and HBL

Hadasit (www.hadasit.co.il), the technology transfer company of Hadassah Medical
Organization (HMO) in Jerusalem, Israel, promotes and commercializes HMO`s
continuously generated intellectual property (IP) and R&D capabilities. IP
generated by HMO has already gained global recognition due to Hadasit`s
successful enterprising of Hadassah`s biomedical technology, including novel
therapeutics, diagnostics and devices.

Hadasit Bio Holdings (TASE:HDST), (www.hbl.co.il), is the publicly traded
holding company of Hadasit, the technology transfer company of Hadassah Medical
Organization. HBL was founded in 2005 for the purpose of advancing the knowledge
and experience accumulated in the Hadassah University Hospital Research
Laboratories. HBL has a portfolio of nine biotechnology companies, all of which
have proven success at the feasibility stage; all have demonstrated efficacy of
a medication/s in animal models and are before clinical trials. HBL`s companies
are all developing medications for billion dollar markets and have blockbuster
potential. Fields of focus include cancer, inflammatory diseases and tissue
rehabilitation by means of stem cells, all of which Hadassah University Hospital
possesses vast knowledge and is known as a world leader. The company was issued
in January 2006 and raised up to date approximately 20 million dollars from the
public and from a strategic investor.

About Hadassah University Medical Center

The Hadassah University Medical Center (www.hadassah.org.il) is a
state-of-the-art medical center incorporating all medical and surgical
sub-specialties. With a 750 beds tertiary care referral hospital at Ein Kerem
and a 300 bed community hospital on Mt. Scopus, Hadassah University Medical
Center in Jerusalem conductshalf of the hospitalresearch in Israel. The flagship
of Hadassah, the Women's Zionist Organization of America, which laid the
foundation of Israel's medical infrastructure, initiated and maintains
educational programs and youth institutions, and is the main supporter of The
Hadassah Medical Center, which is committed to excellence in health care,
medical research and medical education. Together with the Hebrew University,
Hadassah runs five academic schools of medical professions. Hadassah treats
everybody, regardless of race, religion, gender, ethnicity or political
persuasion, and provides medical services to nearly one million people annually.

About Hadassah Clinical Research Center

The Hadassah Clinical Research Center (HCRC) is the Phase I Clinical Trial Unit
of the Hadassah University Hospital located at The Hadassah Medical Center
Hebrew University Biotechnology Park (JBP-Jerusalem BioPark) Ein-Kerem. The HCRC
is a joint venture of the Clinical Pharmacology Unit of the Division of Medicine
and Hadasit, the technology transfer company of Hadassah University Hospitals.
Professor Yoseph Caraco, a clinical pharmacologist with an international
reputation in clinical and laboratory research, leads a dedicated team of
professionals trained to conduct research with the highest international
standards. The staff at the 15 bed HCRC unit has years of experience working
with local and international pharmaceutical, biotechnology, medical device and
CRO companies, offering a complete package of services and facilities for drug
and device clinical studies. For more information about the HCRC, please
contact: liron@hadassah.org.il.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6000448&lang=en

Hadassah Ein Kerem Hospital
Ron Krumer, +972-50-728-1626
Spokesperson
ron@hadassah.org.il
or
Hadasit
Marjie Hadad, +972-54-536-5220
Media Liaison
marjie@netvision.net.il

Copyright Business Wire 2009